CN1163267C - Glp-1或类似物在中风中的用途 - Google Patents

Glp-1或类似物在中风中的用途 Download PDF

Info

Publication number
CN1163267C
CN1163267C CNB998113077A CN99811307A CN1163267C CN 1163267 C CN1163267 C CN 1163267C CN B998113077 A CNB998113077 A CN B998113077A CN 99811307 A CN99811307 A CN 99811307A CN 1163267 C CN1163267 C CN 1163267C
Authority
CN
China
Prior art keywords
glp
gly
ala
glu
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998113077A
Other languages
English (en)
Chinese (zh)
Other versions
CN1322137A (zh
Inventor
S�����ҵϿ�
S·埃芬迪克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1322137A publication Critical patent/CN1322137A/zh
Application granted granted Critical
Publication of CN1163267C publication Critical patent/CN1163267C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Mechanical Light Control Or Optical Switches (AREA)
  • Complex Calculations (AREA)
CNB998113077A 1998-09-24 1999-09-22 Glp-1或类似物在中风中的用途 Expired - Fee Related CN1163267C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10171998P 1998-09-24 1998-09-24
US60/101,719 1998-09-24

Publications (2)

Publication Number Publication Date
CN1322137A CN1322137A (zh) 2001-11-14
CN1163267C true CN1163267C (zh) 2004-08-25

Family

ID=22286048

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998113077A Expired - Fee Related CN1163267C (zh) 1998-09-24 1999-09-22 Glp-1或类似物在中风中的用途

Country Status (12)

Country Link
EP (1) EP1115421B1 (https=)
JP (1) JP2002526454A (https=)
CN (1) CN1163267C (https=)
AT (1) ATE433324T1 (https=)
AU (1) AU766375B2 (https=)
BR (1) BR9913932A (https=)
CA (1) CA2344056A1 (https=)
DE (1) DE69940975D1 (https=)
ES (1) ES2325777T3 (https=)
MY (1) MY155270A (https=)
TW (1) TWI260986B (https=)
WO (1) WO2000016797A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003532691A (ja) * 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
CN103356996A (zh) 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
CN1561224A (zh) * 2001-10-01 2005-01-05 伊莱利利公司 降低与严重疾病相关的死亡率和发病率的方法
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20030199445A1 (en) 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
PL209734B1 (pl) 2002-02-20 2011-10-31 Emisphere Tech Inc Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
CA2608311C (en) 2005-05-13 2012-11-27 Eli Lilly And Company Glp-1 pegylated compounds
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
US8765669B2 (en) 2008-06-17 2014-07-01 Glytech, Inc. Glycosylated GLP-1 peptide
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
WO2010129248A1 (en) 2009-05-06 2010-11-11 Centocor Ortho Biotech Inc. Melanocortin receptor binding conjugates
KR20120101037A (ko) 2009-10-30 2012-09-12 오츠카 가가쿠 가부시키가이샤 항원성 ｇｌｐ?１ 아날로그의 당쇄 부가체
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
JP6039569B2 (ja) * 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US20160122406A1 (en) * 2013-06-07 2016-05-05 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
PT3257524T (pt) 2015-02-11 2020-11-27 Gmax Biopharm Llc Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica
CN105254720B (zh) * 2015-11-18 2018-10-09 暨南大学 一种多受体激动剂po13及应用
WO2018113340A1 (zh) * 2016-12-20 2018-06-28 中国药科大学 多肽p11及其用途
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN115397455A (zh) * 2020-01-16 2022-11-25 上海仁会生物制药股份有限公司 Glp-1给药方案
US20240050531A1 (en) * 2020-12-16 2024-02-15 The Chinese University Of Hong Kong A method for reversing aging brain functional decline
CN116970062B (zh) * 2022-04-29 2024-04-09 南京知和医药科技有限公司 一种超长效glp-1多肽衍生物及其制备方法和用途
CN119909159A (zh) * 2022-06-23 2025-05-02 广州银诺医药集团股份有限公司 一种改进的glp-1受体激动剂的融合蛋白在治疗疾病中的用途
CN119744271A (zh) 2022-09-08 2025-04-01 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用
CN119569847A (zh) * 2024-12-03 2025-03-07 中国科学院上海有机化学研究所 Glp-1变体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
EP1049486A4 (en) * 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS

Also Published As

Publication number Publication date
MY155270A (en) 2015-09-30
AU6398599A (en) 2000-04-10
BR9913932A (pt) 2001-10-16
EP1115421A2 (en) 2001-07-18
JP2002526454A (ja) 2002-08-20
AU766375B2 (en) 2003-10-16
ES2325777T3 (es) 2009-09-16
WO2000016797A2 (en) 2000-03-30
ATE433324T1 (de) 2009-06-15
DE69940975D1 (de) 2009-07-23
WO2000016797A3 (en) 2000-05-25
CA2344056A1 (en) 2000-03-30
TWI260986B (en) 2006-09-01
CN1322137A (zh) 2001-11-14
EP1115421B1 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
CN1163267C (zh) Glp-1或类似物在中风中的用途
CN1268391C (zh) 外周给予的glp－1类似物和衍生物在控制肥胖中的用途
CN1571676A (zh) Glp－1和胰岛素的双相混合物
CN1305897C (zh) 新肽化合物和其制备方法及含有它们的药物组合物
CN1229390C (zh) 降低血液葡萄糖水平的肽
CN1635832A (zh) 施用glp－1分子的方法
CN1195777C (zh) 新的速效胰岛素衍生物
CN1635900A (zh) Glp－1和基础胰岛素的预混合物
CN1080123C (zh) 肽的延长释放
CN1329620A (zh) 胰高血糖素样肽－1的类似物
CN1832959A (zh) 聚乙二醇连接的glp－1化合物
CN1564828A (zh) 作为glp－1受体激动剂和胰高血糖素拮抗剂的肽及其在药学上的使用方法
CN1703424A (zh) Glp－1衍生物及其经粘膜吸收的制剂
CN1893980A (zh) 与白蛋白样物质相连的新glp－1类似物
CN1070500C (zh) 甲状旁腺激素类似物和甲状旁腺激素相关肽：合成和治疗骨质疏松症的用途
CN1133598A (zh) 酰化的胰岛素
CN101035568A (zh) 使用包含glp－1的运铁蛋白融合蛋白的组合治疗
CN1922313A (zh) 酸性α－糖苷酶及其片段
CN1501809A (zh) 应用胰高血糖素样促胰岛肽的长期治疗方案
CN1384755A (zh) 新型exendin激动剂制剂及其给药方法
CN1454214A (zh) 具有增高功效的修饰生物肽
CN1867360A (zh) 治疗肽的清蛋白结合型衍生物
CN1176947C (zh) 用于治疗骨质疏松症的甲状旁腺激素类似物
CN1622822A (zh) 含有生长素释放肽的药物组合物
CN1187203A (zh) 治疗由皮质甾类诱发的骨质减少的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040825

Termination date: 20091022